Your session is about to expire
← Back to Search
aQIVc Vaccine for Flu in Adults 50+
Study Summary
This trial will study the safety & effectiveness of 3 flu vaccines in 7700 adults age 50+ with or without health conditions.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How secure are the outcomes of those receiving investigational aQIVc treatments?
"After careful review, the safety of aQIVc was rated 3 on our scale due to prior clinical evidence confirming its efficacy and multiple studies that back up its safety."
Are there still opportunities to enroll in the study?
"According to the records available on clinicaltrials.gov, this research investigation is currently seeking patients. The initial posting was made on November 3rd 2023 and pertinent updates were recently applied on November 7th of the same year."
How many locations are conducting this investigation in the urban area?
"Patients can enroll at 49 different clinic locations across Europe, such as emovis GmbH in Dresden, Klinische Forschung Dresden GmbH in Essen, and Studienzentrum Bocholderstrasse in Hamburg."
How many subjects are taking part in the current research?
"Seqirus is looking to enrol 7,700 suitable participants for their clinical trial across two locations: emovis GmbH in Dresden, Alberta and Klinische Forschung Dresden GmbH in Essen, Ontario."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger